BRWA
HRTX icon

B. Riley Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

B. Riley Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.27K Sell
12,103
-14
-0.1% -$11 ﹤0.01% 912
2026
Q1 		$9.04K Hold
12,117
– – ﹤0.01% 876
2025
Q4 		$15.8K Hold
12,117
– – ﹤0.01% 1009
2025
Q3 		$15.3K Sell
12,117
-373
-3% -$591 ﹤0.01% 1046
2025
Q2 		$25.9K Hold
12,490
– – ﹤0.01% 1011
2025
Q1 		$27.5K Sell
12,490
-112
-0.9% -$217 ﹤0.01% 1291
2024
Q4 		$19.3K Hold
12,602
– – ﹤0.01% 1131
2024
Q3 		$26.1K Buy
12,602
+1,000
+9% +$2.39K ﹤0.01% 1248
2024
Q2 		$40.6K Buy
+11,602
New +$35.6K ﹤0.01% 1351
2024
Q1 		– Sell
-11,490
Closed -$19.5K – 1480
2023
Q4 		$19.5K Buy
+11,490
New +$12.7K ﹤0.01% 1372
2019
Q2 		– Sell
-30,686
Closed -$750K – 807
2019
Q1 		$750K Buy
30,686
+150
+0.5% +$3.93K 0.09% 237
2018
Q4 		$793K Sell
30,536
-6,116
-17% -$168K 0.11% 192
2018
Q3 		$1.16M Buy
36,652
+6,266
+21% +$233K 0.14% 166
2018
Q2 		$1.18M Sell
30,386
-10,300
-25% -$328K 0.16% 156
2018
Q1 		$1.12M Sell
40,686
-51,200
-56% -$1.16M 0.16% 153
2017
Q4 		$1.66M Buy
91,886
+23,310
+34% +$380K 0.22% 120
2017
Q3 		$1.11M Buy
68,576
+21,700
+46% +$340K 0.18% 134
2017
Q2 		$650K Buy
+46,876
New +$679K 0.12% 208
2015
Q1 		– Sell
-1,077
Closed -$11K – 1197
2014
Q4 		$11K Buy
+1,077
New +$8.79K ﹤0.01% 2815
2014
Q3 		– Sell
-1,077
Closed -$13.3K – 1195
2014
Q2 		$13.3K Buy
+1,077
New +$12.9K ﹤0.01% 1657

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

B. Riley Wealth Advisors's HRTX Position: Q2 2026 in Review

B. Riley Wealth Advisors reduced its Heron Therapeutics (HRTX) stake by 0.12% in Q2 2026, selling an estimated $11 and leaving 12,103 shares worth $5.27K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

B. Riley Wealth Advisors first reported a position in HRTX in Q2 2014 and has held it in 20 quarters since. The position peaked at $1.66M in Q4 2017. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • B. Riley Wealth Advisors held 12,103 shares of Heron Therapeutics worth $5.27K as of Q2 2026.
  • B. Riley Wealth Advisors sold 14 Heron Therapeutics shares in Q2 2026, an estimated $11.
  • Heron Therapeutics made up ﹤0.01% of B. Riley Wealth Advisors's portfolio in Q2 2026, its #912 holding.
  • B. Riley Wealth Advisors first reported a position in Heron Therapeutics in Q2 2014 and has held it in 20 quarters since.
  • B. Riley Wealth Advisors's Heron Therapeutics position peaked at $1.66M in Q4 2017.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.